Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer

Cisplatin-based chemoradiation is the standard treatment for cervical cancer, but chemosensitizing strategies are needed to improve patient survival. EGFR (Epidermal Growth Factor Receptor) is an oncogene overexpressed in cervical cancer that is involved in chemoresistance. Recent studies showed tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hugo de Almeida, Vitor, Guimarães, Isabella dos Santos, Almendra, Lucas R., Rondon, Araci M.R., Tilli, Tatiana M., de Melo, Andréia C., Sternberg, Cinthya, Monteiro, Robson Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078136/
https://www.ncbi.nlm.nih.gov/pubmed/30093972
http://dx.doi.org/10.18632/oncotarget.25748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078136/
https://www.ncbi.nlm.nih.gov/pubmed/30093972
http://dx.doi.org/10.18632/oncotarget.25748

Ejemplares similares